LY2428757

LY2428757 is a pegylated synthetic analog of glucagon-like peptide 1 (GLP-1) developed by Eli Lilly and Company for the treatment of type 2 diabetes mellitus. As a GLP-1 receptor agonist, it mimics the action of endogenous GLP-1, a hormone secreted by intestinal cells that plays an important role in regulating blood glucose levels. LY2428757 was designed to be administered as a once-weekly subcutaneous injection and aimed to improve glycemic control in patients with type 2 diabetes inadequately managed with diet, exercise, or metformin therapy. The drug entered phase 2 clinical trials but development was discontinued after these studies[1][2][3].